BiotechTube

Tideglusib + Placebo

Phase 2/3Completed
1 views this week 0 watching💤 Quiet
Interest: 28/100
28
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Congenital Myotonic Dystrophy

Conditions

Congenital Myotonic Dystrophy

Trial Timeline

Mar 3, 2021 → Apr 4, 2023

NCT ID
NCT03692312

About Tideglusib + Placebo

Tideglusib + Placebo is a phase 2/3 stage product being developed by AMO Pharma for Congenital Myotonic Dystrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT03692312. Target conditions include Congenital Myotonic Dystrophy.

What happened to similar drugs?

5 of 20 similar drugs in Congenital Myotonic Dystrophy were approved

Approved (5) Terminated (0) Active (15)
✅turoctocog alfaNovo NordiskApproved
✅eptacog alfa (activated) + Feiba VHNovo NordiskApproved
✅activated recombinant human factor VIINovo NordiskApproved
✅activated recombinant human factor VII + activated recombinant human factor VII + factor VIIINovo NordiskApproved
✅Lipiodol Ultra Fluid with surgical gluesGuerbetApproved
🔄turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
🔄turoctocog alfa pegolNovo NordiskPhase 3

Hype Score Breakdown

Clinical
15
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06174220Phase 2Recruiting
NCT03692312Phase 2/3Completed

Competing Products

20 competing products in Congenital Myotonic Dystrophy

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
20
TideglusibAMO PharmaPhase 2/3
35
EDIT-101Editas MedicinePhase 1/2
18
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
KW-3357Kyowa KirinPhase 1
29
Pasireotide 0.6Mg Solution for Injection + Saline SolutionNovartisPhase 2
27
Sandostatine LPNovartisPhase 2
35
mycophenolate mofetilRochePhase 1
29
turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
40
catridecacog + recombinant factor XIIINovo NordiskPhase 1
29
activated recombinant human factor VIINovo NordiskPhase 2
35
turoctocog alfa pegolNovo NordiskPhase 3
40
recombinant factor XIIINovo NordiskPre-clinical
26
activated recombinant human factor VII, long acting + activated recombinant human factor VII, long actingNovo NordiskPhase 1
29
Advate® + turoctocog alfaNovo NordiskPhase 1
29
nonacog beta pegolNovo NordiskPhase 3
40